Equity
€273,094 ▲ 23.3%
CBKX Pharma has made a profit in every financial year since 2021.
CBKX Pharma
Lifetime
5 annual accounts with figures on one time axispeak €298,907 (2021)
€232,301▼ 5.7%
peak €100,139 (2021)
€51,547▲ 3.9%
peak €273,094 (2025)
€273,094▲ 23.3%
€502,467▼ 14.1%
peak 2 FTE (2024)
-not published
Board1 name since 2020
1 director
Documentsfilings and deeds
27-08-202627 days late
2025abbreviated format
Equity from €221,547 to €273,094
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 26,973 companies had the same profile as CBKX Pharma has now. Each dot stands for 68 companies, two years later.
94.9%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,973 companies, not a prediction for CBKX Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0749625106
Incorporation
Founding capital of €20,000, 100 shares · Founder: · Appointment: (director) · published on 03-07-2020 · Gazette deed
First establishment
Apotheek Potuit, Antwerpsesteenweg 375, Ghent
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| CBKX Pharma Ghent | €775,561 | €232,301 | 35.2% | - |
| Het Apotheekhuis Beveren-Kruibeke-Zwijndrecht | €720,768 | €231,228 | 32.2% | 1.1 |
| PHARMACIE DELDICQUE-LENFANT SRL Tournai | €785,310 | €244,060 | 25.2% | 1.8 |
| PHARMACIE MONTENEGRO Anderlecht | €791,126 | €248,171 | 10.3% | 2.5 |
| APOTHEEK ANN-SOPHIE COPPIN Knokke-Heist | €845,739 | €250,018 | 27.7% | 0.6 |
| PHARMACIE FERMEUSE-BRISMEE Charleroi | €869,675 | €220,873 | -2.5% | 2.5 |
| PHARMACIE RIGO ROSETTE Spa | €689,241 | €245,245 | 37.6% | 2.4 |
These companies have the same main activity as CBKX Pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €689,000 and €870,000, founded between 2019 and 2021.
Official details
Source: KBO- Status
- Active since 01-07-2020Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2023
- Establishment unit
- 2.304.631.8099040 Ghent, since 01-07-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 08-01-2025
Annual accounts 2025
- ≈ €1.1mestimated
- €775,561▼ 3.8%
- Employeeson 31-12-2025
- 1▼ 50.0%
- Filing
- Filed on 27-08-2026
Insights on CBKX Pharma
CBKX Pharma files the abbreviated format. That format states no turnover. The gross margin fell from €298,907 in 2021 to €232,301 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about CBKX Pharma
- What is the company number of CBKX Pharma?
- The company number of CBKX Pharma is 0749.625.106. The VAT number is the same number with BE in front: BE 0749.625.106.
- Where is CBKX Pharma based?
- The registered office is at Antwerpsesteenweg 375, 9040 Ghent.Company details
- What does CBKX Pharma do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of CBKX Pharma?
- CBKX Pharma is a private limited company (BV).
- When was CBKX Pharma founded?
- CBKX Pharma was founded on 01-07-2020.
- Is CBKX Pharma still active?
- Yes, CBKX Pharma is an active enterprise in the KBO register.
- How many employees does CBKX Pharma have?
- CBKX Pharma had an average of 1.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does CBKX Pharma fall under?
- In its 2023 annual accounts, CBKX Pharma states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of CBKX Pharma?
- The turnover in financial year 2025 is ≈ €1.1m. This figure is estimated from the gross margin of €232,301 and 43 comparable companies (NACE 477). It probably lies between €710,000 and €2.3m.
- Is CBKX Pharma profitable?
- In financial year 2025, CBKX Pharma made a profit of €51,547.
- Where can I find the annual accounts of CBKX Pharma?
- CBKX Pharma filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CBKX Pharma due?
- CBKX Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.